Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial

The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic c...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2021-09, Vol.154, p.296-306
Main Authors: Denda, Tadamichi, Takashima, Atsuo, Gamoh, Makio, Iwanaga, Ichiro, Komatsu, Yoshito, Takahashi, Masanobu, Nakamura, Masato, Ohori, Hisatsugu, Sakashita, Akiko, Tsuda, Masahiro, Kobayashi, Yoshimitsu, Baba, Hideo, Kotake, Masanori, Ishioka, Chikashi, Yamada, Yasuhide, Sato, Atsushi, Yuki, Satoshi, Morita, Satoshi, Takahashi, Shin, Yamaguchi, Tatsuro, Shimada, Ken
Format: Article
Language:English
Subjects:
5-Fluorouracil
Bevacizumab
Cancer
Chemotherapy
Colorectal cancer
Colorectal carcinoma
Combination therapy
Confidence intervals
Data analysis
FOLFOX
Irinotecan
IRIS
Metastases
Metastasis
Monoclonal antibodies
Oxaliplatin
Patients
Sidedness
SIRB
Survival
Targeted cancer therapy
Tumors
XELOX
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC). Overall survival (OS) data were immature at the time of the primary analysis. In total, 487 patients from 53 institutions with previously untreated mCRC were randomly assigned (1:1) to receive either mFOLFOX6/CapeOX plus bevacizumab (control group) or S-1 and irinotecan plus bevacizumab (experimental group; 3- or 4-week regimen). The final OS data were analysed from follow-up data collected until 30th September 2017. With a median follow-up period of 48.7 months, median survival times were 32.6 and 34.3 months (hazard ratio [HR]: 0.89, 95% confidence interval [CI]: 0.72–1.10, P = 0.293) and median PFS durations were 10.8 and 14.0 months in the control and experimental groups, respectively (HR: 0.86, 95% CI: 0.71–1.04, P 
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2021.06.013